Expert Opinion on Investigational Drugs, Volume 31, Issue 6 (2022)

Browse this journal
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Expert Opinion on Investigational Drugs, Volume 31, Issue 6 (2022)

See all volumes and issues
Vol 33, 2024 Vol 32, 2023 Volume 31, 2022 Vol 30, 2021 Vol 29, 2020 Vol 28, 2019 Vol 27, 2018 Vol 26, 2017 Vol 25, 2016 Vol 24, 2015 Vol 23, 2014 Vol 22, 2013 Vol 21, 2012 Vol 20, 2011 Vol 19, 2010 Vol 18, 2009 Vol 17, 2008 Vol 16, 2007 Vol 15, 2006 Vol 14, 2005 Vol 13, 2004 Vol 12, 2003 Vol 11, 2002 Vol 10, 2001 Vol 9, 2000 Vol 8, 1999 Vol 7, 1998 Vol 6, 1997 Vol 5, 1996 Vol 4, 1995 Vol 3, 1994
Download citations Download PDFs Download issue

Breast Cancer

Editorial

Editorial
Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential
Alessandro Rizzo, Antonio Cusmai, Silvana Acquafredda, Lucia Rinaldi & Gennaro Palmiotti
Pages: 495-498
Published online: 17 Feb 2022
First Page PreviewforLadiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential | Full Text | References | PDF (612.5 KB) | EPUB
  • 7019 Views
  • 13 CrossRef citations
  • 0Altmetric
Free Access

Review

Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development
Paolo Tarantino, Gabriele Antonarelli, Liliana Ascione & Giuseppe Curigliano
Pages: 499-513
Published online: 26 Sep 2021
AbstractforInvestigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development | Full Text | References | PDF (1.9 MB) | EPUB
  • 363 Views
  • 5 CrossRef citations
  • 0Altmetric
Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer
Ya-Chi Chen, Jiajie Yu, Ciara Metcalfe, Tom De Bruyn, Thomas Gelzleichter, Vikram Malhi, Pablo D. Perez-Moreno & Xiaojing Wang
Pages: 515-529
Published online: 25 Oct 2021
AbstractforLatest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer | Full Text | References | PDF (655.6 KB) | EPUB
  • 11729 Views
  • 13 CrossRef citations
  • 0Altmetric
Open Access
The emerging role of immune checkpoint inhibitors for the treatment of breast cancer
Frederick M. Howard, Dario Villamar, Gong He, Alexander T. Pearson & Rita Nanda
Pages: 531-548
Published online: 11 Oct 2021
AbstractforThe emerging role of immune checkpoint inhibitors for the treatment of breast cancer | Full Text | References | PDF (456.7 KB) | EPUB
  • 4374 Views
  • 9 CrossRef citations
  • 0Altmetric
Open Access
Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond
Alessandro Rizzo & Angela Dalia Ricci
Pages: 549-555
Published online: 25 Nov 2021
AbstractforBiomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond | Full Text | References | PDF (1.8 MB) | EPUB
  • 1283 Views
  • 40 CrossRef citations
  • 0Altmetric
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects
Alessandro Rizzo, Angela Dalia Ricci, Laura Lanotte, Lucia Lombardi, Alessandro Di Federico, Giovanni Brandi & Gennaro Gadaleta-Caldarola
Pages: 557-565
Published online: 13 Dec 2021
AbstractforImmune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects | Full Text | References | PDF (1.2 MB) | EPUB
  • 453 Views
  • 22 CrossRef citations
  • 0Altmetric
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer
Elisa Agostinetto, Agnese Losurdo, Guilherme Nader-Marta, Armando Santoro, Kevin Punie, Romualdo Barroso, Lazar Popovic, Cinzia Solinas, Marleen Kok, Evandro de Azambuja & Matteo Lambertini
Pages: 567-591
Published online: 09 Mar 2022
AbstractforProgress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer | Full Text | References | PDF (2.5 MB) | EPUB
  • 2422 Views
  • 9 CrossRef citations
  • 0Altmetric
CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress
Chiara Corti, Konstantinos Venetis, Elham Sajjadi, Lorenzo Zattoni, Giuseppe Curigliano & Nicola Fusco
Pages: 593-605
Published online: 24 Mar 2022
AbstractforCAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress | Full Text | References | PDF (1.3 MB) | EPUB
  • 1942 Views
  • 10 CrossRef citations
  • 0Altmetric
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers
Linjie Luo & Khandan Keyomarsi
Pages: 607-631
Published online: 03 May 2022
AbstractforPARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers | Full Text | References | PDF (1.1 MB) | EPUB
  • 965 Views
  • 7 CrossRef citations
  • 0Altmetric
Clinical development of antibody-drug conjugates in triple negative breast cancer: can we jump higher?
Dimitrios Zardavas
Pages: 633-644
Published online: 02 May 2022
AbstractforClinical development of antibody-drug conjugates in triple negative breast cancer: can we jump higher? | Full Text | References | PDF (1 MB) | EPUB
  • 468 Views
  • 1 CrossRef citations
  • 0Altmetric

Explore articles